Associated tags: Diamond, BRAF, CNS, GBM, EGFR, Brain, RAF, NRAS, Therapy, NSCLC, Patient, Cancer, Pharmaceutical industry, M26 Modular Accessory Shotgun System, Black Diamond, Conference, MAP, Drug discovery
Locations: NEW YORK, BOSTON, NY, CALIFORNIA, CAMBRIDGE, MA, US, BLACK DIAMOND, KRAS
Retrieved on:
Wednesday, January 18, 2023
Diamond,
Yale University,
Corporate development,
Partnership,
Gilead,
Drug discovery,
Leukemia,
Therapy,
Yale New Haven Hospital,
LLS,
CGI,
Science,
Gilead Sciences,
Faculty,
MAP,
G1 Therapeutics,
Washington University in St. Louis,
Black Diamond,
FDA,
M26 Modular Accessory Shotgun System,
IND,
Senior advisor,
Senior,
Management and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons.
Key Points:
- and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons.
- “Bob’s counsel, expertise and partnership have been invaluable to Black Diamond, and on behalf of the Board of Directors, I would like to thank him for his contributions to the company.
- It has been a pleasure serving as the Chairman of the company’s Board of Directors and I am confident that Black Diamond is well positioned for future success with its compelling science, robust pipeline and industry leading management team.
- I am pleased to have partnered with the team and the Board and will continue to support Black Diamond from the sidelines,” said Robert A. Ingram.
Retrieved on:
Monday, December 12, 2022
Diamond,
Drug design,
Drug discovery,
Annual report,
Antibody,
Black Diamond,
Initial public offering,
New Enterprise Associates,
Cancer,
Biotechnology,
Mab,
NEA,
IPO,
MAP,
General partnership,
Versant,
Precision medicine,
Therapy,
M26 Modular Accessory Shotgun System,
Patient,
Pharmaceutical industry,
Medical imaging,
Launch pad (disambiguation) CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics, Inc. (Launchpad), an antibody-focused precision oncology company, together with a $30 million Series A investment by founding investors, Versant Ventures and New Enterprise Associates (NEA).
Key Points:
- and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics, Inc. (Launchpad), an antibody-focused precision oncology company, together with a $30 million Series A investment by founding investors, Versant Ventures and New Enterprise Associates (NEA).
- “When we launched Black Diamond in 2018, the field of precision oncology was still in its early days.
- Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
- Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options.
Retrieved on:
Wednesday, November 9, 2022
Diamond,
GLOBE,
MAP,
Piper Sandler Companies,
Nasdaq,
Drug discovery,
M26 Modular Accessory Shotgun System,
Cancer,
Conference,
Patient,
NEW,
Black Diamond,
Pharmaceutical industry and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that company management will participate in three upcoming investor conferences:
Key Points:
- and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that company management will participate in three upcoming investor conferences:
The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference.
- Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
- Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options.
- Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Retrieved on:
Tuesday, November 8, 2022
Diamond,
IND,
Research,
Development,
BRAF,
Family,
G&A,
Therapy,
Brain,
Glioblastoma,
Senior,
Company,
Program,
Treatment,
Administration,
Black Diamond,
RAF,
Food,
Drug discovery,
TKI,
PDX,
II,
U.S. Securities and Exchange Commission,
Cancer,
Neoplasm,
Patient,
Private Securities Litigation Reform Act,
Investigational New Drug,
MAPK,
Mutation,
Nasdaq,
European Organisation for Research and Treatment of Cancer,
GBM,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
R,
Achievement,
Penetrance,
Poster,
EGFR,
CNS,
FDA,
MAP,
GLOBE,
III,
EORTC,
Investment,
Large-cell lung carcinoma,
M26 Modular Accessory Shotgun System,
Annual report,
DevOps,
FGFR,
NEW,
Pharmaceutical industry,
Management,
Medical imaging,
NSCLC and NEW YORK,, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Key Points:
- and NEW YORK,, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
- Net cash used in operations was $16.5 million for the third quarter of 2022 compared to $26.5 million for the third quarter of 2021.
- Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
- Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Retrieved on:
Wednesday, October 26, 2022
The poster presentations highlight new preclinical data demonstrating robust anti-tumor activity of both programs in a broad range of preclinical models of oncogene driven cancers.
Key Points:
- The poster presentations highlight new preclinical data demonstrating robust anti-tumor activity of both programs in a broad range of preclinical models of oncogene driven cancers.
- These preclinical results demonstrate our compelling approach to precision cancer medicines through our MAP Drug Discovery Engine and MasterKey therapies.
- Our MAP Drug Discovery Engine provides Black Diamond with a scalable approach to validate the oncogenicity of previously uncharacterized mutations.
- The posters from the EORTC-NCI-AACR Symposium are available on the Scientific Presentations and Publications section of the Black Diamond Therapeutics website.
Retrieved on:
Tuesday, September 6, 2022
Diamond,
Cancer,
Master key,
Therapy,
Morgan,
Morgan Stanley,
Black Diamond,
NEW,
GLOBE,
Conference,
Nasdaq,
Webcast,
Drug discovery,
Patient,
MAP,
Pharmaceutical industry Black Diamond Therapeutics management will also participate in investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference being held from Monday, September 12th to Wednesday, September 14th, 2022, in New York, NY.
Key Points:
- Black Diamond Therapeutics management will also participate in investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference being held from Monday, September 12th to Wednesday, September 14th, 2022, in New York, NY.
- Black Diamond Therapeutics is a clinical-stage precision oncology medicine company pioneering the development of novel Master Key therapies.
- Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery.
- Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Diamond,
FDA,
Regulation of tobacco by the U.S. Food and Drug Administration,
III,
U.S. Securities and Exchange Commission,
Association,
American Association,
Drug discovery,
GLOBE,
Black Diamond,
NEW,
R,
Private Securities Litigation Reform Act,
Investment,
Cancer,
M26 Modular Accessory Shotgun System,
IND,
HER2,
Annual report,
Ishiyama,
Glioblastoma,
NSCLC,
Patient,
GBM,
Company,
Large-cell lung carcinoma,
EGFR,
II,
Program,
FGFR,
MAP,
G&A,
BRAF,
AACR,
Research,
American Association for Cancer Research,
Nasdaq,
Development,
Brain,
Administration,
Food,
Investigational New Drug,
Pharmaceutical industry,
Medical imaging and NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Key Points:
- and NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
- Net cash used in operations was $18.1 million for the second quarter of 2022 compared to $25.2 million for the second quarter of 2021.
- Research and Development Expenses: Research and development (R&D) expenses were $16.2 million for the second quarter of 2022 compared to $26.7 million for the second quarter of 2021.
- General and Administrative Expenses: General and administrative (G&A) expenses were $7.0 million for the second quarter of 2022, compared to $8.0 million for the second quarter of 2021.
Retrieved on:
Wednesday, August 3, 2022
Diamond,
Quanta,
Black Diamond,
Drug discovery,
Wedbush Securities,
Nasdaq,
M26 Modular Accessory Shotgun System,
Cancer,
Oncology,
Patient,
Conference,
NEW,
GLOBE,
Targets,
Webcast,
MAP,
Pharmaceutical industry Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
Key Points:
- Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
- Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options.
- Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery.
- Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .
Diamond,
Conference,
M26 Modular Accessory Shotgun System,
Webcast,
Cancer,
Nasdaq,
GLOBE,
Patient,
MAP,
NEW,
Drug discovery,
Black Diamond,
Pharmaceutical industry Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
Key Points:
- Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.
- Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options.
- Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery.
- Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .
Diamond,
Leadership,
Achievement,
Large-cell lung carcinoma,
Company,
Rucaparib,
Program,
Board of directors,
EGFR,
Glioblastoma,
M26 Modular Accessory Shotgun System,
First Pavlov State Medical University of St. Petersburg,
Immunity (medical),
Roche,
Gaps,
Cancer,
ImClone Systems,
Senior,
GBM,
Investigational New Drug,
Research institute,
Nasdaq,
Ovarian cancer,
Growth,
Eli Lilly and Company,
Â,
Patient,
GLOBE,
Private Securities Litigation Reform Act,
MAP,
NEW,
Clovis Oncology,
Board,
Drug discovery,
Merck,
NSCLC,
Homologous recombination,
U.S. Securities and Exchange Commission,
Hematology,
Black Diamond,
Pharmaceutical industry,
Risk management,
IND CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer. In conjunction with the appointment of Dr. Yurasov, Karsten Witt, M.D., is transitioning from his current role as the Company’s Interim Chief Medical Officer to a clinical advisory role.
Key Points:
- and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer.
- We are delighted to welcome Sergey to Black Diamond as Chief Medical Officer.
- Dr. Yurasov joins Black Diamond Therapeutics from Nuvation Bio, an oncology therapeutics company.
- Dr. Yurasov succeeds Dr. Witt, who was Black Diamonds founding Chief Medical Officer and will continue to support the Company in an advisory capacity.
